SGMOQ · Sangamo Therapeutics, Inc
$0.15
+0.00 (+1.51%)
At close · Oct 2
Return incl. dividend (before tax)
Going-concern doubt
— flagged May 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Our history of significant losses, negative cash flows from operations, negative working capital, limited liquidity resources currently on hand and dependence on our ability to obtain additional financing to fund our operations have resulted in management's assessment that there is substantial doubt about our ability to continue as a going concern for at least the next 12 months from the date the financial statements included in this Quarterly Report are issued.”View the 10-Q filed May 14, 2026
Market Cap
$58.00M
Shares
414.29M
Volume · Oct 2
1.6M
Avg daily vol (3M)
2.74M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$0.15
Open$0.15
Day$0.14–0.15
52W close$0.04–0.74
Avg vol 30d2.1M
Short int10.7M · 2.6% float · 3.2d
Short vol60%
Last earningsMay 14, 2026
DataJan 2020–Oct 2026
Filing10-Q · May 14
Up next
filed May 14, 2026
call held May 14, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
—
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
—
Year over year · more shares
Price change (1Y)
-78.9%
Trailing year
Short interest
2.6%
Latest settlement · 3.2 days to cover
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Neutral
Momentum
Very Weak
Sentiment
Bearish
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 15.3 · calm
Equity put/call 0.58
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−39%
below
Price vs 50-day avg
+8%
above
RSI (14)
52
neutral
MACD trend
Negative
52-week position
15%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−11%
trailing
6-month return
−43%
trailing
YTD return
−65%
this year
Relative strength
−55%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $0 › 200d $0 — 200d above 50d
Institutional flow
Distributing
-94% holders QoQ · +2 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
2.59% of float · ▲ +2.8% MoM · 3.2 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr low
7 holders — near 3-yr low, contrarian setup
Squeeze score
58
elevated · 0–100
Fundamentals
Revenue growth
+89%
Y/Y
EPS growth
+10%
Y/Y
Free cash flow
$-97.3M
Quant / Vol
risk profile
Volatility
161%
annualized · 1-yr
Max drawdown
−95%
past year
ATR
8.1%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed May 14, 2026
Total operating expenses
· 2026
$110M – $130M
Non-GAAP total operating expenses
· 2026
$100M – $120M
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−39%
Bearish
Price vs 50-day avg
+8%
Bullish
RSI (14)
52
Neutral
MACD trend
Negative
Bearish
52-week position
15%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross)
No cross
50d $0 › 200d $0 — 200d above 50d
Institutional flow
Distributing
-94% holders QoQ · +2 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
2.59% of float · ▲ +2.8% MoM · 3.2 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr low
7 holders — near 3-yr low, contrarian setup
Price context
position in its 52-week range
Range low $0
Now $0 · 15%
Range high $1
vs 200-day avg -39%
vs 50-day avg +8%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
SGMOQ
this stock
Sangamo Therapeutics, Inc
|
$58.00M | -64.9% | +88.6% | — | 2.6% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$133.37B | +11.3% | +46.2% | 30.7 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$81.13B | -4.8% | +20.8% | 19.5 | 2.5% |
|
MRNA
Moderna, Inc.
|
$79.40B | +544.3% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$61.25B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| SGMOQ | +2.4% | -11.3% | -43.3% | +0.3% | -64.9% |
| SPY | -0.2% | -0.5% | +12.2% | +0.9% | +12.9% |
| vs SPY | +2.7% | -10.8% | -55.5% | -0.6% | -77.7% |